Reformatting Rituximab into Human IgG2 and IgG4 Isotypes Dramatically Improves Apoptosis Induction In Vitro
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Reformatting Rituximab into Human IgG2 and IgG4 Isotypes Dramatically Improves Apoptosis Induction In Vitro
Authors
Keywords
Apoptosis, Cross-linking, Antibody isotypes, Cysteine, Cell binding, Engineering and technology, Flow cytometry, Protein engineering
Journal
PLoS One
Volume 10, Issue 12, Pages e0145633
Publisher
Public Library of Science (PLoS)
Online
2015-12-30
DOI
10.1371/journal.pone.0145633
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies
- (2015) Ann L. White et al. CANCER CELL
- Engineering disulfide bonds within an antibody
- (2014) Yoshihisa Hagihara et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- The Fab Conformations in the Solution Structure of Human Immunoglobulin G4 (IgG4) Restrict Access to Its Fc Region
- (2014) Lucy E. Rayner et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Accelerated therapeutic progress in diffuse large B cell lymphoma
- (2013) Qingqing Cai et al. ANNALS OF HEMATOLOGY
- Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties
- (2013) Christian Klein et al. mAbs
- Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions
- (2013) Christian Kellner et al. METHODS
- Isotype and glycoform selection for antibody therapeutics
- (2012) Roy Jefferis ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway
- (2012) J. Honeychurch et al. BLOOD
- Disulfide bond structures of IgG molecules
- (2012) Hongcheng Liu et al. mAbs
- Molecular engineering to improve antibodies’ anti-lymphoma activity
- (2011) Matthias Peipp et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- CD20 antibodies: doing the time warp
- (2011) M. S. Cragg BLOOD
- Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies
- (2011) W. Alduaij et al. BLOOD
- Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies
- (2011) G. Niederfellner et al. BLOOD
- Optimizing Therapeutic Antibody Function
- (2010) Etsuji Kaneko et al. BIODRUGS
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
- (2010) E. Mossner et al. BLOOD
- Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions
- (2010) Gregory L. Moore et al. mAbs
- Mutations within a human IgG2 antibody form distinct and homogeneous disulfide isomers but do not affect Fc gamma receptor or C1q binding
- (2010) Sandra Lightle et al. PROTEIN SCIENCE
- CD20-Targeted Therapy: The Next Generation of Antibodies
- (2010) Tom van Meerten et al. SEMINARS IN HEMATOLOGY
- Rituximab: Mechanism of Action
- (2010) George J. Weiner SEMINARS IN HEMATOLOGY
- Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood
- (2009) Shigeru Iida et al. BMC CANCER
- Engineered therapeutic antibodies with improved effector functions
- (2009) Tsuguo Kubota et al. CANCER SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search